Merck’s Januvia sales top 18.8 billion won in first half

The US based Merck’s Januvia has gained its momentum as its sales of its flagship model posted 18.8 billion won, up a whopping 189.2 percent from the same period of last year.

Januvia, a pill that was approved by the US Food and Drug Administration in October of 2006, lowered blood-sugar to acceptable levels in 67 percent of diabetics participating in the study, when the drug was combined w...